Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetrahydrodeoxyuridine is a synthetic pyrimidine nucleoside analogue. It is designed to inhibit cytidine deaminase, an enzyme involved in nucleotide metabolism. By inhibiting this enzyme, tetrahydrodeoxyuridine prevents the deamination of cytidine and 2'-deoxycytidine, thereby modulating the metabolism of nucleosides and enhancing the efficacy of certain chemotherapeutic agents that are susceptible to degradation by cytidine deaminase. This mechanism can increase the effectiveness of drugs such as cytarabine or gemcitabine by prolonging their half-life and activity in vivo[2]. The compound has been investigated primarily as a biomodulator in oncology settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetrahydrodeoxyuridine.